Browsing by Author "Baptiste S"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Programme science methodologies and practices that address "FURRIE" challenges: examples from the field.
    (2024-Jul) Hargreaves JR; Baptiste S; Bhattacharjee P; Cowan FM; Herce ME; Lauer K; Sikazwe I; Geng E; Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.; Liverpool School of Tropical Medicine, Liverpool, UK.; Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, USA.; International Treatment Preparedness Coalition, Johannesburg, South Africa.; CIDRZ, Lusaka, Zambia.; Institute for Global Public Health, University of Manitoba, Winnipeg, Manitoba, Canada.; Partners for Health and Development in Africa, Nairobi, Kenya.; Division of Infectious Diseases and Center for Dissemination and Implementation, Washington University in St. Lous, St. Louis, Missouri, USA.; CeSHHAR, Harare, Zimbabwe.
    INTRODUCTION: "Programme science" deploys scientific methods to address questions that are a priority to support the impact of public health programmes. As such, programme science responds to the challenges of making such studies: (1) feasible to undertake, (2) useful, (3) rigorous, (4) real-world-relevant, (5) informative, and undertaken by (6) equitable partnerships. The acronym "FURRIE" is proposed to describe this set of six challenges. This paper discusses selected HIV/STI (sexually transmitted infection) programme science case studies to illustrate how programme science rises to the FURRIE challenges. DISCUSSION: One way in which programme science is made more feasible is through the analysis and interpretation of data collected through service delivery. For some questions, these data can be augmented through methods that reach potential clients of services who have not accessed services or been lost to follow-up. Process evaluation can enhance the usefulness of programme science by studying implementation processes, programme-client interactions and contextual factors. Ensuring rigour by limiting bias and confounding in the real-world context of programme science studies requires methodological innovation. Striving for scientific rigour can also have the unintended consequence of creating a gap between what happens in a study, and what happens in the "real-world." Community-led monitoring is one approach to grounding data collection in the real-world experience of clients. Evaluating complex, context-specific strategies to strengthen health outcomes in a way that is informative for other settings requires clear specification of the intervention packages that are planned and delivered in practice. Programme science provides a model for equitable partnership through co-leadership between programmes, researchers and the communities they serve. CONCLUSIONS: Programme science addresses the FURRIE challenges, thereby improving programme impact and ultimately health outcomes and health equity. The adoption and adaptation of the types of novel programme science approaches showcased here should be promoted within and beyond the HIV/STI field.
  • Thumbnail Image
    Item
    The case for an HIV cure and how to get there.
    (2021-Jan) Dybul M; Attoye T; Baptiste S; Cherutich P; Dabis F; Deeks SG; Dieffenbach C; Doehle B; Goodenow MM; Jiang A; Kemps D; Lewin SR; Lumpkin MM; Mathae L; McCune JM; Ndung'u T; Nsubuga M; Peay HL; Pottage J; Warren M; Sikazwe I; Global Health Division, The Bill & Melinda Gates Foundation, Seattle, WA, USA.; Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia.; Agence Nationale de Recherches sur le SIDA et les Hepatites Virales, Paris, France.; RTI International, Research Triangle Park, NC, USA.; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Rockville, MD, USA.; Viiv Healthcare, Brentford, UK.; International Treatment Preparedness Coalition, Johannesburg, South Africa.; Center for Global Health Practice and Impact, Georgetown University, Washington, DC, USA. Electronic address: mrd54@georgetown.edu.; Sommartel, London, UK.; Africa Health Research Institute, Durban, South Africa; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban South Africa; Max Planck Institute for Infection Biology, Berlin, Germany; University College London, London, UK.; AIDS Vaccine Advocacy Coalition, New York, NY, USA.; McKinsey & Company Secondee at The Bill & Melinda Gates Foundation, Seattle, WA, USA.; Joint Adherent Brothers & Sisters Against AIDS, Kampala, Uganda.; Kenya Ministry of Health, Nairobi, Kenya.; University of California, San Francisco, California, USA.; Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.; Center for Global Health Practice and Impact, Georgetown University, Washington, DC, USA.; Office of AIDS Research, National Institutes of Health, Department of Health and Human Services, Rockville, MD, USA.; CIDRZ; Centre for Infectious Disease Research in Zambia (CIDRZ)
    In light of the increasing global burden of new HIV infections, growing financial requirements, and shifting funding landscape, the global health community must accelerate the development and delivery of an HIV cure to complement existing prevention modalities. An effective curative intervention could prevent new infections, overcome the limitations of antiretroviral treatment, combat stigma and discrimination, and provide a sustainable financial solution for pandemic control. We propose steps to plan for an HIV cure now, including defining a target product profile and establishing the HIV Cure Africa Acceleration Partnership (HCAAP), a multidisciplinary public-private partnership that will catalyse and promote HIV cure research through diverse stakeholder engagement. HCAAP will convene stakeholders, including people living with HIV, at an early stage to accelerate the design, social acceptability, and rapid adoption of HIV-cure products.